Gene Therapy's Reimbursement Problem Has Not Gone Away

The promise of gene therapy has always been straightforward: a single treatment that cures a disease, eliminating a lifetime of chronic care costs. The economic logic, in theory, should be compelling for payers. In practice, it has proved anything but.

Despite a decade of scientific progress and several approved products — including therapies for sickle cell disease, haemophilia, and spinal muscular atrophy — the reimbursement landscape for gene therapies remains treacherous. Prices in the range of $1 million to $3.5 million per patient have stalled uptake and created political flashpoints in the US and Europe alike.

The fundamental tension is structural: manufacturers need to recoup years of R&D spending and the cost of manufacturing complex biologics in a single transaction, while payers — who may not retain the patient long enough to realise the savings — resist paying for outcomes they cannot guarantee.

Outcomes-based contracts, once touted as the solution, have proved difficult to administer. Tracking patients across health systems, attributing outcomes, and clawing back payments if a therapy fails are all operationally burdensome. Several early deal structures have quietly collapsed.